Sofinnova

Press

 

Portfolio News

Jun 05, 2023

Ascendis Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany

Ascendis Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany

Portfolio News

Jun 05, 2023

Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease

Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease

Portfolio News

May 31, 2023

Ascendis Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Portfolio News

May 31, 2023

RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

Portfolio News

May 23, 2023

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

Portfolio News

May 22, 2023

Quanta Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

Quanta Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors

Sofinnova News

May 16, 2023

Sofinnova Welcomes Dr. Jakob Dupont as Executive Partner

Sofinnova Welcomes Dr. Jakob Dupont as Executive Partner

Event

May 15, 2023

Maha Katabi to join panel at Yale Innovation Summit “State of the Biotech Venture Market 2023” on Thursday, June 1 at 10:00am ET

Maha Katabi to join panel at Yale Innovation Summit “State of the Biotech Venture Market 2023” on Thursday, June 1 at 10:00am ET

Portfolio News

May 01, 2023

Atsena Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

Atsena Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

Portfolio News

Apr 27, 2023

Antiva Biosciences Closes $53 Million Series E Equity Financing and Names Kristine Ball President and CEO

Antiva Biosciences Closes $53 Million Series E Equity Financing and Names Kristine Ball President and CEO

Portfolio News

Mar 29, 2023

Bolt Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

Bolt Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

Portfolio News

Mar 27, 2023

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing

Portfolio News

Mar 24, 2023

Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Portfolio News

Mar 23, 2023

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

Sofinnova News

Mar 22, 2023

Sofinnova Supporting Female Biotech Executives

Sofinnova Supporting Female Biotech Executives

Portfolio News

Mar 20, 2023

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Portfolio News

Mar 20, 2023

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

Sofinnova News

Mar 15, 2023

Regina Salvat Featured in Biomarker: “23 Biotech VCs in '23”

Regina Salvat Featured in Biomarker: “23 Biotech VCs in '23”

Portfolio News

Feb 24, 2023

Acquisition of CinCor Pharma by AstraZeneca Completed

Acquisition of CinCor Pharma by AstraZeneca Completed

Portfolio News

Feb 21, 2023

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat

Portfolio News

Feb 08, 2023

Atsena to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)

Atsena to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)

Portfolio News

Jan 26, 2023

XyloCor Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

XyloCor Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Event

Jan 11, 2023

Maha Katabi to join Endpoints "Capital Markets" Panel on January 11 at 10:30am PT

Maha Katabi to join Endpoints "Capital Markets" Panel on January 11 at 10:30am PT

Portfolio News

Jan 09, 2023

CinCor Pharma to be Acquired by AstraZeneca

CinCor Pharma to be Acquired by AstraZeneca

Portfolio News

Jan 05, 2023

NorthSea Provides Clinical Update Reflecting Progress Across NASH and Metabolic Disorders Programmes

NorthSea Provides Clinical Update Reflecting Progress Across NASH and Metabolic Disorders Programmes

Portfolio News

Jan 04, 2023

RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

Portfolio News

Jan 03, 2023

Vera Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Portfolio News

Dec 01, 2022

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases

Sofinnova News

Dec 01, 2022

Maha Katabi Featured in BioWorld: "Venture Financing: Less Zoom but Still Plenty of Capital in Correcting Market"

Maha Katabi Featured in BioWorld: "Venture Financing: Less Zoom but Still Plenty of Capital in Correcting Market"

Portfolio News

Nov 28, 2022

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension

Event

Nov 18, 2022

Maha Katabi to join Demy-Colton's Virtual Salon Panel "Raising Money In This Market: Can It Be Done?" on November 30 at 11am EST

Maha Katabi to join Demy-Colton's Virtual Salon Panel "Raising Money In This Market: Can It Be Done?" on November 30 at 11am EST

Portfolio News

Nov 17, 2022

Aerovate Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Aerovate Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Portfolio News

Nov 14, 2022

Ascendis Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Ascendis Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Event

Nov 08, 2022

Chris Carpenter to join "BioCentury Scene Setter Report: Does East-West Matter?" during the BioCentury Inc. BayHelix Summit on November 15 at 9am PST

Chris Carpenter to join "BioCentury Scene Setter Report: Does East-West Matter?" during the BioCentury Inc. BayHelix Summit on November 15 at 9am PST

Portfolio News

Nov 07, 2022

CinCor Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension

CinCor Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension

Portfolio News

Nov 05, 2022

Vera Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection

Vera Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection

Portfolio News

Oct 31, 2022

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

Portfolio News

Oct 26, 2022

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

Portfolio News

Oct 18, 2022

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

Portfolio News

Oct 03, 2022

Y-mAbs Announces Pivotal Data for Omburtamab

Y-mAbs Announces Pivotal Data for Omburtamab

Event

Sep 19, 2022

Maha Katabi to join "Battling Biotech's Bear Market" Panel at the Fierce Biotech Summit on September 19th at 9:45AM ET

Maha Katabi to join "Battling Biotech's Bear Market" Panel at the Fierce Biotech Summit on September 19th at 9:45AM ET

Portfolio News

Sep 13, 2022

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer

Portfolio News

Sep 13, 2022

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss

Portfolio News

Aug 15, 2022

CinCor Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

CinCor Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Portfolio News

Aug 12, 2022

Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Karuna Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Portfolio News

Aug 08, 2022

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Portfolio News

Aug 08, 2022

CinCor Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension

CinCor Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension

Portfolio News

Aug 08, 2022

Karuna Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Karuna Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Portfolio News

Jul 26, 2022

CinCor Doses Last Patient in Phase 2 Study and Announce Initiation of Long-Term Extension Study for Baxdrostat in Uncontrolled Hypertension

CinCor Doses Last Patient in Phase 2 Study and Announce Initiation of Long-Term Extension Study for Baxdrostat in Uncontrolled Hypertension

Portfolio News

Jul 19, 2022

Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency

Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency

Portfolio News

Jul 12, 2022

Y-mAbs’ Announces Clearance of IND for GD2-SADA

Y-mAbs’ Announces Clearance of IND for GD2-SADA

Portfolio News

Jul 06, 2022

Vera Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Portfolio News

Jun 16, 2022

Inozyme Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

Inozyme Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

Event

Jun 07, 2022

David Kabakoff to join Panel Discussion during BIO: "Next Gen Oncology Therapeutics: Changing the Cancer Landscape" on June 14 at 11:00am PT

David Kabakoff to join Panel Discussion during BIO: "Next Gen Oncology Therapeutics: Changing the Cancer Landscape" on June 14 at 11:00am PT

Portfolio News

Jun 04, 2022

Vera Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

Vera Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

Portfolio News

Jun 01, 2022

CinCor Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

CinCor Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease

Portfolio News

May 31, 2022

Regeneron has completed its acquisition of Checkmate Pharmaceuticals

Regeneron has completed its acquisition of Checkmate Pharmaceuticals

Portfolio News

May 26, 2022

Pionyr Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022

Pionyr Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022

Portfolio News

May 23, 2022

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

Sofinnova News

Apr 05, 2022

Sofinnova Investments Announces the Addition of Dr. Chris Carpenter as Executive Partner

Sofinnova Investments Announces the Addition of Dr. Chris Carpenter as Executive Partner

Portfolio News

Apr 04, 2022

Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Inozyme Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Event

Mar 31, 2022

Sarah Bhagat to join Panel Discussion: "Investing in IRD Cures" at Investing in Cures Summit on April 2nd at 3:00pm PT

Sarah Bhagat to join Panel Discussion: "Investing in IRD Cures" at Investing in Cures Summit on April 2nd at 3:00pm PT

Portfolio News

Mar 28, 2022

Apellis Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Apellis Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Portfolio News

Mar 18, 2022

CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes

CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes

Portfolio News

Mar 16, 2022

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)

Sofinnova News

Mar 15, 2022

Regina Salvat Selected by Venture Forward as One of Ten Women in VC: Rising Stars to Watch

Regina Salvat Selected by Venture Forward as One of Ten Women in VC: Rising Stars to Watch

Portfolio News

Mar 13, 2022

Ascendis Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

Ascendis Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

Portfolio News

Mar 08, 2022

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314

Portfolio News

Mar 02, 2022

Natera and MinMinBear Foundation Announce Partnership to Provide Comfort and Support to Kidney Patients

Natera and MinMinBear Foundation Announce Partnership to Provide Comfort and Support to Kidney Patients

Event

Feb 22, 2022

Sarah Bhagat to join Panel Discussion: Changing Lanes in Biotech Investing at Global Life Science Partnering Conference on February 23 at 12:45pm PT

Sarah Bhagat to join Panel Discussion: Changing Lanes in Biotech Investing at Global Life Science Partnering Conference on February 23 at 12:45pm PT

Portfolio News

Feb 18, 2022

Gyroscope Therapeutics Acquisition is Complete

Gyroscope Therapeutics Acquisition is Complete

Portfolio News

Feb 14, 2022

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Event

Feb 03, 2022

Maha Katabi to join panel at Ontario Bioscience Innovation Organization’s Investment Summit on February 11 at 2:30PM ET

Maha Katabi to join panel at Ontario Bioscience Innovation Organization’s Investment Summit on February 11 at 2:30PM ET

Portfolio News

Jan 14, 2022

Ascendis Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Portfolio News

Jan 07, 2022

CinCor Pharma Announces Pricing of Initial Public Offering

CinCor Pharma Announces Pricing of Initial Public Offering

Portfolio News

Jan 06, 2022

Antiva Biosciences Named Winner of Global Women’s HealthTech Award by World Bank Group and Consumer Technology Association

Antiva Biosciences Named Winner of Global Women’s HealthTech Award by World Bank Group and Consumer Technology Association

Portfolio News

Dec 22, 2021

Novartis to Acquire Gyroscope Therapeutics for Up to $1.5 Billion

Novartis to Acquire Gyroscope Therapeutics for Up to $1.5 Billion

Portfolio News

Dec 17, 2021

ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Portfolio News

Dec 17, 2021

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

Portfolio News

Dec 17, 2021

NorthSea Therapeutics Completes $80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

NorthSea Therapeutics Completes $80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

Portfolio News

Dec 15, 2021

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

Portfolio News

Nov 16, 2021

NorthSea Announces Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity

NorthSea Announces Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity

Portfolio News

Nov 08, 2021

Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million

Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million

Portfolio News

Nov 02, 2021

Antiva Biosciences Closes $31 Million Series D Equity Financing

Antiva Biosciences Closes $31 Million Series D Equity Financing

Portfolio News

Oct 26, 2021

Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs

Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs

Portfolio News

Oct 12, 2021

CinCor Pharma Raises $143 Million in Series B Financing

CinCor Pharma Raises $143 Million in Series B Financing

Portfolio News

Oct 07, 2021

NextCure Announces Publication of Preclinical Data for NC410

NextCure Announces Publication of Preclinical Data for NC410

Portfolio News

Oct 04, 2021

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program

Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program

Portfolio News

Sep 30, 2021

Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005

Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005

Event

Sep 30, 2021

Sarah Bhagat to join "Making Smart Investments" panel during Longwood Healthcare Leaders Meeting on October 4 at 5:10pm ET

Sarah Bhagat to join "Making Smart Investments" panel during Longwood Healthcare Leaders Meeting on October 4 at 5:10pm ET

Portfolio News

Sep 29, 2021

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

Event

Sep 23, 2021

Maha Katabi to join panel during Johnson & Johnson webinar on "Battling Chronic Kidney Disease (CKD)" on Tuesday, September 28 at 10:30am PT.

Maha Katabi to join panel during Johnson & Johnson webinar on "Battling Chronic Kidney Disease (CKD)" on Tuesday, September 28 at 10:30am PT.

Portfolio News

Sep 13, 2021

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

Portfolio News

Sep 08, 2021

Bolt Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo®

Bolt Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo®

Portfolio News

Aug 25, 2021

Ascendis Announces U.S. Food and Drug Administration Approval of SKYTROFA®, the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Announces U.S. Food and Drug Administration Approval of SKYTROFA®, the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Portfolio News

Aug 11, 2021

Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug

Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug

Portfolio News

Jul 27, 2021

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Portfolio News

Jul 27, 2021

ObsEva and Organon Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

ObsEva and Organon Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Portfolio News

Jul 07, 2021

Neurana Pharmaceuticals Announces Publication in Pain Management

Neurana Pharmaceuticals Announces Publication in Pain Management

Portfolio News

Jul 06, 2021

Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease

Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease

Portfolio News

Jul 06, 2021

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

Portfolio News

Jul 06, 2021

Ascendis Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP)

Ascendis Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP)

Portfolio News

Jun 29, 2021

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

Portfolio News

Jun 25, 2021

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA

Portfolio News

Jun 24, 2021

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

Portfolio News

Jun 23, 2021

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Portfolio News

Jun 22, 2021

Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients

Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients

Portfolio News

Jun 22, 2021

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids

Event

Jun 11, 2021

Sarah Bhagat to join Panel Discussion on Neurological Disorder Therapeutics at Biotech by the Lake Summit on Tuesday, June 22 at 10:25am CST

Sarah Bhagat to join Panel Discussion on Neurological Disorder Therapeutics at Biotech by the Lake Summit on Tuesday, June 22 at 10:25am CST

Portfolio News

Jun 09, 2021

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

Portfolio News

Jun 07, 2021

Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

Portfolio News

Jun 04, 2021

VISEN Pharmaceuticals obtained IND approval for phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone)

VISEN Pharmaceuticals obtained IND approval for phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone)

Portfolio News

Jun 02, 2021

Bolt Biotherapeutics and Genmab Announce Oncology Research and Development Collaboration

Bolt Biotherapeutics and Genmab Announce Oncology Research and Development Collaboration

Portfolio News

May 14, 2021

Apellis Announces FDA Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Apellis Announces FDA Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Portfolio News

May 13, 2021

Vera Therapeutics Announces Pricing of Initial Public Offering

Vera Therapeutics Announces Pricing of Initial Public Offering

Portfolio News

May 04, 2021

Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404

Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404

Portfolio News

Apr 29, 2021

Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency

Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency

Portfolio News

Apr 28, 2021

Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer

Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer

Portfolio News

Apr 28, 2021

Pfizer Acquires Amplyx Pharmaceuticals

Pfizer Acquires Amplyx Pharmaceuticals

Portfolio News

Apr 27, 2021

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

Event

Apr 23, 2021

Sarah Bhagat to join Investor Roundtable at the Virtual Neuroscience Innovation Forum (NIF) hosted by Sachs Associates on April 28 at 2:40pm ET

Sarah Bhagat to join Investor Roundtable at the Virtual Neuroscience Innovation Forum (NIF) hosted by Sachs Associates on April 28 at 2:40pm ET

Portfolio News

Apr 20, 2021

Y-mAbs Provides Regulatory Update on Omburtamab

Y-mAbs Provides Regulatory Update on Omburtamab

Portfolio News

Apr 19, 2021

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial

Portfolio News

Apr 16, 2021

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Portfolio News

Apr 13, 2021

Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Portfolio News

Apr 01, 2021

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Portfolio News

Mar 31, 2021

Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing

Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing

Portfolio News

Mar 30, 2021

Amarin Receives European Commission (Ec) Approval for Vazkepa to Reduce Cardiovascular Risk

Amarin Receives European Commission (Ec) Approval for Vazkepa to Reduce Cardiovascular Risk

Portfolio News

Mar 30, 2021

VISEN’s TransConTM Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Schedule

VISEN’s TransConTM Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Schedule

Portfolio News

Mar 29, 2021

Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

Portfolio News

Mar 26, 2021

Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing

Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing

Portfolio News

Mar 22, 2021

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease

Portfolio News

Mar 18, 2021

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Portfolio News

Mar 12, 2021

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency

Sofinnova News

Feb 22, 2021

Jim Healy Receives 2021 NVCA "Excellence in Healthcare Innovation" Award for his Commitment to Improving the Lives of Patients Through Science

Jim Healy Receives 2021 NVCA "Excellence in Healthcare Innovation" Award for his Commitment to Improving the Lives of Patients Through Science

Portfolio News

Feb 17, 2021

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

Portfolio News

Feb 10, 2021

ObsEva Provides Business Outlook for 2021

ObsEva Provides Business Outlook for 2021

Portfolio News

Feb 04, 2021

Bolt Biotherapeutics Prices Upsized Initial Public Offering

Bolt Biotherapeutics Prices Upsized Initial Public Offering

Portfolio News

Jan 21, 2021

Athira Pharma Announces Pricing of Public Offering of Common Stock

Athira Pharma Announces Pricing of Public Offering of Common Stock

Portfolio News

Jan 19, 2021

Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

Sofinnova News

Jan 12, 2021

Sofinnova's Chief Legal Officer Hooman Shahlavi featured in Vanguard Law Magazine

Sofinnova's Chief Legal Officer Hooman Shahlavi featured in Vanguard Law Magazine

Portfolio News

Jan 11, 2021

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

Akouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory Neuropathy

Portfolio News

Jan 09, 2021

VISEN Closes $150 Million Series B Financing to Accelerate the Development & Commercialization of its Innovative Endocrinology Therapies in Greater China

VISEN Closes $150 Million Series B Financing to Accelerate the Development & Commercialization of its Innovative Endocrinology Therapies in Greater China

Portfolio News

Jan 08, 2021

Positive Phase 2b ICONA interim Results for Icosabutate in NASH Patients

Positive Phase 2b ICONA interim Results for Icosabutate in NASH Patients

Portfolio News

Jan 07, 2021

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

Portfolio News

Jan 04, 2021

Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

Portfolio News

Dec 30, 2020

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program

Portfolio News

Dec 21, 2020

Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study

Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study

Sofinnova News

Dec 21, 2020

Sarah Bhagat featured in BioWorld: Gene Therapy Surges as Risks Reduced

Sarah Bhagat featured in BioWorld: Gene Therapy Surges as Risks Reduced

Portfolio News

Dec 18, 2020

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe

Portfolio News

Dec 18, 2020

Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

Portfolio News

Dec 17, 2020

Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab

Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab

Portfolio News

Dec 16, 2020

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program

Portfolio News

Dec 10, 2020

ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids

Portfolio News

Dec 08, 2020

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease

Portfolio News

Dec 08, 2020

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS Effects Study

Sofinnova News

Dec 08, 2020

Sarah Bhagat Selected as One of Ten Winners for Biocom’s 2020 Life Science Catalyst Award

Sarah Bhagat Selected as One of Ten Winners for Biocom’s 2020 Life Science Catalyst Award

Portfolio News

Dec 08, 2020

Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab

Checkmate Pharmaceuticals Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate CMP-001 in Combination with Nivolumab

Portfolio News

Dec 03, 2020

Natera Announced Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies

Natera Announced Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies

Portfolio News

Dec 01, 2020

Athira Pharma Announces Initiation of Patient Dosing for Treatment of Mild-to-Moderate Alzheimer’s Disease

Athira Pharma Announces Initiation of Patient Dosing for Treatment of Mild-to-Moderate Alzheimer’s Disease

Event

Dec 01, 2020

Maha Katabi to join panel: "The Future of Biotech Financing: Continued Boom or Bust?" on December 3rd at 1pm ET

Maha Katabi to join panel: "The Future of Biotech Financing: Continued Boom or Bust?" on December 3rd at 1pm ET

Portfolio News

Nov 25, 2020

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

Portfolio News

Nov 23, 2020

Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research

Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research

Portfolio News

Nov 19, 2020

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of Vascepa® (Icosapent Ethyl) in Mainland China

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of Vascepa® (Icosapent Ethyl) in Mainland China

Portfolio News

Nov 18, 2020

Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial

Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial

Portfolio News

Nov 18, 2020

Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

Portfolio News

Nov 16, 2020

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

Portfolio News

Nov 16, 2020

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Portfolio News

Nov 05, 2020

Merck to Acquire VelosBio

Merck to Acquire VelosBio

Portfolio News

Oct 23, 2020

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe

Portfolio News

Oct 19, 2020

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

Portfolio News

Oct 07, 2020

Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation & Rare Pediatric Disease Designation by FDA

Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation & Rare Pediatric Disease Designation by FDA

Portfolio News

Oct 06, 2020

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

Portfolio News

Sep 28, 2020

Sanofi Completes Principia Biopharma Inc. Acquisition

Sanofi Completes Principia Biopharma Inc. Acquisition

Portfolio News

Sep 17, 2020

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease

Portfolio News

Sep 17, 2020

Athira Pharma Announces Pricing of Initial Public Offering

Athira Pharma Announces Pricing of Initial Public Offering

Portfolio News

Sep 16, 2020

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

Portfolio News

Sep 15, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Portfolio News

Sep 14, 2020

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

Portfolio News

Sep 08, 2020

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ hGH

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ hGH

Portfolio News

Aug 17, 2020

Sanofi to Acquire Principia Biopharma

Sanofi to Acquire Principia Biopharma

Portfolio News

Aug 12, 2020

Ascendis Pharma Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Ascendis Pharma Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe

Portfolio News

Aug 06, 2020

Aerovate Therapeutics Emerges With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy

Aerovate Therapeutics Emerges With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy

Portfolio News

Jul 30, 2020

Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Portfolio News

Jul 28, 2020

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration

Portfolio News

Jul 27, 2020

Checkmate Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade

Checkmate Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade

Portfolio News

Jul 27, 2020

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Portfolio News

Jul 27, 2020

Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA®

Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA®

Portfolio News

Jul 23, 2020

Inozyme Pharma Announces Pricing of Initial Public Offering

Inozyme Pharma Announces Pricing of Initial Public Offering

Portfolio News

Jul 21, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Portfolio News

Jul 20, 2020

Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial Of Novel Antifungal Fosmanogepix

Amplyx Announces Positive Top-Line Data in Phase 2 Clinical Trial Of Novel Antifungal Fosmanogepix

Portfolio News

Jul 20, 2020

Checkmate Pharmaceuticals Executes a Snappy 1-2 Biotech Gambit — Big Crossover Followed by an Instant IPO

Checkmate Pharmaceuticals Executes a Snappy 1-2 Biotech Gambit — Big Crossover Followed by an Instant IPO

Portfolio News

Jul 17, 2020

Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals

Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals

Portfolio News

Jul 16, 2020

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Portfolio News

Jul 14, 2020

Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)

Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)

Portfolio News

Jul 08, 2020

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Portfolio News

Jul 07, 2020

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

Portfolio News

Jul 06, 2020

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

Portfolio News

Jul 06, 2020

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan

Portfolio News

Jun 30, 2020

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA

Portfolio News

Jun 29, 2020

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY

Portfolio News

Jun 26, 2020

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Portfolio News

Jun 26, 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Portfolio News

Jun 25, 2020

Akouos Announces Pricing of Initial Public Offering

Akouos Announces Pricing of Initial Public Offering

Portfolio News

Jun 23, 2020

Karuna Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Portfolio News

Jun 23, 2020

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Portfolio News

Jun 15, 2020

Vascepa® Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified & Post Hoc Subgroup Analyses

Vascepa® Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified & Post Hoc Subgroup Analyses

Portfolio News

Jun 12, 2020

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Portfolio News

Jun 10, 2020

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Portfolio News

Jun 04, 2020

Athira Pharma Closes $85 Million Series B Financing

Athira Pharma Closes $85 Million Series B Financing

Portfolio News

May 14, 2020

Inozyme Pharma & GACI Global Initiate Patient Study to Improve Understanding of the Impact of Disease in Patients with ENPP1 Deficiency & ABCC6 Deficiency

Inozyme Pharma & GACI Global Initiate Patient Study to Improve Understanding of the Impact of Disease in Patients with ENPP1 Deficiency & ABCC6 Deficiency

Portfolio News

May 14, 2020

Vascepa® Shows Significant Reduction in Coronary Revascularization in Prespecified Tertiary Endpoint Analyses

Vascepa® Shows Significant Reduction in Coronary Revascularization in Prespecified Tertiary Endpoint Analyses

Portfolio News

May 13, 2020

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Portfolio News

May 13, 2020

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease

Event

Apr 24, 2020

Maha Katabi to join Biotech by the Lake Investor Summit Panel: "Financing and Investing in Oncology Biotech"

Maha Katabi to join Biotech by the Lake Investor Summit Panel: "Financing and Investing in Oncology Biotech"

Portfolio News

Apr 22, 2020

AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus

Portfolio News

Apr 22, 2020

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Portfolio News

Apr 19, 2020

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial

Portfolio News

Apr 16, 2020

Natera Prices $250 Million Convertible Senior Notes Due 2027

Natera Prices $250 Million Convertible Senior Notes Due 2027

Portfolio News

Apr 15, 2020

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

Portfolio News

Apr 15, 2020

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering

Portfolio News

Apr 01, 2020

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

Sofinnova News

Mar 31, 2020

Sofinnova Investments Strengthens Executive Team with the Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD

Sofinnova Investments Strengthens Executive Team with the Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD

Sofinnova News

Mar 17, 2020

Sofinnova Investments Announces the Addition of Jonathan Leff, M.D. as Executive Partner

Sofinnova Investments Announces the Addition of Jonathan Leff, M.D. as Executive Partner

Portfolio News

Mar 03, 2020

Akouos Closes $105 Million Series B Financing

Akouos Closes $105 Million Series B Financing

Portfolio News

Feb 26, 2020

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

Portfolio News

Feb 14, 2020

Promedior Announces Completion of Acquisition by Roche

Promedior Announces Completion of Acquisition by Roche

Event

Feb 07, 2020

Maha Katabi to Present at the "Meet with Series" hosted by Johnson & Johnson Innovation, JLABS

Maha Katabi to Present at the "Meet with Series" hosted by Johnson & Johnson Innovation, JLABS

Event

Feb 05, 2020

Jason Pitts to Moderate Bio CEO and & Investor Conference Panel: "Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs"

Jason Pitts to Moderate Bio CEO and & Investor Conference Panel: "Neuroscience at the Crossroads: Late Stage Brain Disorder Pipelines and Unmet Needs"

Event

Jan 20, 2020

Jim Healy to join SuperReturn 2020 Panel: "Keeping Things Private or Going Public - Considering the Exit"

Jim Healy to join SuperReturn 2020 Panel: "Keeping Things Private or Going Public - Considering the Exit"

Portfolio News

Jan 15, 2020

Astellas Completes Acquisition of Audentes Therapeutics

Astellas Completes Acquisition of Audentes Therapeutics

Portfolio News

Jan 13, 2020

Chiasma Announces FDA Acceptance Of MYCAPSSA® New Drug Application Resubmission

Chiasma Announces FDA Acceptance Of MYCAPSSA® New Drug Application Resubmission

Portfolio News

Jan 08, 2020

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH

NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH

Event

Dec 17, 2019

Maha Katabi to join Biotech Showcase 2020 Panel "Rare and Orphan Diseases: The Value Proposition of New Modalities vs Established Ones"

Maha Katabi to join Biotech Showcase 2020 Panel "Rare and Orphan Diseases: The Value Proposition of New Modalities vs Established Ones"

Portfolio News

Dec 02, 2019

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutic

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutic

Portfolio News

Nov 20, 2019

Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Portfolio News

Nov 18, 2019

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Portfolio News

Nov 18, 2019

Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Portfolio News

Oct 25, 2019

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

Portfolio News

Oct 21, 2019

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe

Portfolio News

Oct 03, 2019

Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

Event

Oct 01, 2019

Jim Healy to join BIO Investor Forum Panel "Market Outlook—Taking the Temperature of the IPO Market in an Era of Large Pharma M&A"

Jim Healy to join BIO Investor Forum Panel "Market Outlook—Taking the Temperature of the IPO Market in an Era of Large Pharma M&A"

Portfolio News

Sep 26, 2019

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

Portfolio News

Sep 23, 2019

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back

Portfolio News

Sep 12, 2019

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

Akouos Discloses Lead Program, AK-OTOF, a Potential Gene Therapy for Sensorineural Hearing Loss

Portfolio News

Sep 09, 2019

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

Portfolio News

Aug 07, 2019

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

Portfolio News

Aug 05, 2019

Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

Portfolio News

Aug 05, 2019

Natera Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Natera Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies

Portfolio News

Jul 23, 2019

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa®

Chiasma Announces Positive Phase 3 Top-Line Results From CHIASMA OPTIMAL Clinical Trial Of Mycapssa®

Portfolio News

Jul 15, 2019

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria

Portfolio News

Jul 08, 2019

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1

Portfolio News

Jun 27, 2019

Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

Karuna Therapeutics Announces Pricing of Upsized Initial Public Offering

Sofinnova News

May 31, 2019

Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development

Swinging for the Fences: The Dichotomy in Rare Disease Investment and Development

Portfolio News

May 14, 2019

CinCor Pharma Closes $50 Million Series A

CinCor Pharma Closes $50 Million Series A

Sofinnova News

Apr 22, 2019

Sofinnova Investments Announces the Addition of Industry Veteran Maha Katabi, PhD. as a Partner

Sofinnova Investments Announces the Addition of Industry Veteran Maha Katabi, PhD. as a Partner

Portfolio News

Apr 10, 2019

Inozyme Pharma Raises $67 Million in Series A2 Financing

Inozyme Pharma Raises $67 Million in Series A2 Financing

Portfolio News

Mar 28, 2019

Amarin shares new updates to the American Diabetes Association 2019 Standards of Medical Care in Diabetes

Amarin shares new updates to the American Diabetes Association 2019 Standards of Medical Care in Diabetes

Portfolio News

Mar 19, 2019

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation

Portfolio News

Mar 04, 2019

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint

Portfolio News

Feb 25, 2019

Spark Therapeutics Enters into Definitive Merger Agreement with Roche

Spark Therapeutics Enters into Definitive Merger Agreement with Roche

Event

Feb 04, 2019

Jim Healy to join Bio CEO & Investor Panel "Are Record Levels of IPOs Still Disrupting M&A Deals?"

Jim Healy to join Bio CEO & Investor Panel "Are Record Levels of IPOs Still Disrupting M&A Deals?"

Portfolio News

Jan 31, 2019

Kiniksa Pharmaceuticals Announces Pricing of Public Offering

Kiniksa Pharmaceuticals Announces Pricing of Public Offering

Sofinnova News

Jan 25, 2019

A Top VC At a $2B Fund That Invests in Risky Biotechs Reveals How He Finds His Best Investments

A Top VC At a $2B Fund That Invests in Risky Biotechs Reveals How He Finds His Best Investments

Event

Dec 13, 2018

Mike Powell joins AACR Panel "Entrepreneurship in Translational Research"

Mike Powell joins AACR Panel "Entrepreneurship in Translational Research"

Event

Dec 12, 2018

Jim Healy to join East | West CEO Panel "VC Perspectives: Currant Financing Trends in Biotech"

Jim Healy to join East | West CEO Panel "VC Perspectives: Currant Financing Trends in Biotech"

Event

Dec 12, 2018

Jim Healy to join Biotech Showcase Panel "Rare and Orphan Diseases"

Jim Healy to join Biotech Showcase Panel "Rare and Orphan Diseases"

Portfolio News

Dec 06, 2018

XyloCor Therapeutics Raises $17 Million in Series A

XyloCor Therapeutics Raises $17 Million in Series A

Portfolio News

Nov 27, 2018

BioClin Therapeutics Announces Name Change to Rainier Therapeutics

BioClin Therapeutics Announces Name Change to Rainier Therapeutics

Portfolio News

Nov 13, 2018

NextCure Completes a $93M Series B Financing

NextCure Completes a $93M Series B Financing

Portfolio News

Nov 07, 2018

InCarda Completes $42M Oversubscribed Series B Financing

InCarda Completes $42M Oversubscribed Series B Financing

Portfolio News

Nov 05, 2018

NextCure and Lilly Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

NextCure and Lilly Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

Portfolio News

Nov 02, 2018

U.S. FDA Approves Coherus Biosciences' UDENYCA™

U.S. FDA Approves Coherus Biosciences' UDENYCA™

Sofinnova News

Oct 29, 2018

Sarah Bhagat Named as One of the "Nine VCs Who Matter, but You Never Read About"

Sarah Bhagat Named as One of the "Nine VCs Who Matter, but You Never Read About"

Sofinnova News

Oct 16, 2018

Mike Powell and Jason Pitts Featured in EndPoints Guest Column "The Real Cost of Drug Development"

Mike Powell and Jason Pitts Featured in EndPoints Guest Column "The Real Cost of Drug Development"

Portfolio News

Oct 03, 2018

ObsEva Reports Additional Positive Phase 3 Results IMPLANT 2 Trial Following IVF

ObsEva Reports Additional Positive Phase 3 Results IMPLANT 2 Trial Following IVF

Portfolio News

Sep 28, 2018

ObsEva’s Final Results of Phase 2b EDELWEISS Trial Shows Sustained Efficacy and Safety

ObsEva’s Final Results of Phase 2b EDELWEISS Trial Shows Sustained Efficacy and Safety

Portfolio News

Sep 26, 2018

Entasis Therapeutics Announces Pricing of Initial Public Offering

Entasis Therapeutics Announces Pricing of Initial Public Offering

Portfolio News

Sep 25, 2018

Coherus Biosciences Receives European Commission Approval for Udenyca™

Coherus Biosciences Receives European Commission Approval for Udenyca™

Portfolio News

Sep 24, 2018

Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® Capsules Met Primary Endpoint

Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® Capsules Met Primary Endpoint

Portfolio News

Sep 20, 2018

Y-mAbs Therapeutics Announces Pricing of Initial Public Offering

Y-mAbs Therapeutics Announces Pricing of Initial Public Offering

Portfolio News

Sep 19, 2018

Galera Therapeutics Raises $150M

Galera Therapeutics Raises $150M

Portfolio News

Sep 18, 2018

BioClin Therapeutics Announces New Leadership

BioClin Therapeutics Announces New Leadership

Portfolio News

Sep 13, 2018

Principia Biopharma Announces Pricing of Initial Public Offering

Principia Biopharma Announces Pricing of Initial Public Offering

Portfolio News

Aug 16, 2018

A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it.

A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it.

Portfolio News

Aug 07, 2018

Akouos Raises $50M Series A Financing

Akouos Raises $50M Series A Financing

Portfolio News

May 24, 2018

Iterum Announces the Pricing of Initial Public Offering

Iterum Announces the Pricing of Initial Public Offering

Portfolio News

May 23, 2018

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

Portfolio News

May 14, 2018

Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

Portfolio News

May 07, 2018

BioClin Therapeutics, Inc., Completes $50M Series B Financing with Addition of New Investors

BioClin Therapeutics, Inc., Completes $50M Series B Financing with Addition of New Investors

Portfolio News

Mar 28, 2018

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study

Event

Jan 30, 2018

Alan Colowick to Speak at JLABS

Alan Colowick to Speak at JLABS

Portfolio News

Jan 22, 2018

Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine

Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine

Portfolio News

Jan 04, 2018

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO

Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO

Portfolio News

Jan 03, 2018

Ascendis Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone

Ascendis Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone

Portfolio News

Dec 19, 2017

Spark Therapeutics Announces FDA approval of LUXTURNA™

Spark Therapeutics Announces FDA approval of LUXTURNA™

Portfolio News

Dec 18, 2017

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®

Portfolio News

Dec 15, 2017

Aclaris Therapeutics Receives FDA Approval for the Treatment of Raised Seborrheic Keratoses

Aclaris Therapeutics Receives FDA Approval for the Treatment of Raised Seborrheic Keratoses

Portfolio News

Dec 13, 2017

Pionyr Immunotherapeutics Completes $62M Series B Financing

Pionyr Immunotherapeutics Completes $62M Series B Financing

Portfolio News

Nov 29, 2017

Y-mAbs Announces Closing of $30M Extension of Private Equity Placement

Y-mAbs Announces Closing of $30M Extension of Private Equity Placement

Portfolio News

Nov 28, 2017

Medeor Therapeutics Raises $57M In Series B Financing

Medeor Therapeutics Raises $57M In Series B Financing

Portfolio News

Nov 14, 2017

Apellis Announces the Pricing of Initial Public Offering

Apellis Announces the Pricing of Initial Public Offering

Portfolio News

Nov 07, 2017

ObsEva Announces Completion of Patient Recruitment for the Treatment of Endometriosis

ObsEva Announces Completion of Patient Recruitment for the Treatment of Endometriosis

Sofinnova News

Oct 24, 2017

Sofinnova Steps Up

Sofinnova Steps Up

Portfolio News

Sep 27, 2017

NuCana PLC Announces Pricing of Initial Public Offering

NuCana PLC Announces Pricing of Initial Public Offering

Portfolio News

Sep 05, 2017

Entasis Announces $31.9M Extension of Series B Financing

Entasis Announces $31.9M Extension of Series B Financing

Portfolio News

Aug 10, 2017

Apellis Pharmaceuticals Announces $60M Series E Financing

Apellis Pharmaceuticals Announces $60M Series E Financing

Portfolio News

Aug 02, 2017

Amplyx Pharmaceuticals Raises $67M in Series C Financing

Amplyx Pharmaceuticals Raises $67M in Series C Financing

Portfolio News

Jun 15, 2017

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

Art Krieg comes down from the mountain with a $27M round for Checkmate Pharmaceuticals

Event

Jun 09, 2017

Jim Healy to Speak at BIO on Market & Political Pressures

Jim Healy to Speak at BIO on Market & Political Pressures

Event

Jun 07, 2017

Mike Powell to be a Judge at BIO's Start-Up Stadium

Mike Powell to be a Judge at BIO's Start-Up Stadium

Sofinnova News

May 30, 2017

Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership

Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership

Event

Apr 11, 2017

Jim Healy to Speak at Cancer Advance Boston

Jim Healy to Speak at Cancer Advance Boston

Portfolio News

Mar 28, 2017

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

Event

Feb 06, 2017

Charlotte Shropshire to Speak at SuperReturn US West

Charlotte Shropshire to Speak at SuperReturn US West

Sofinnova News

Oct 17, 2016

Sofinnova Raises $650M Biotech-focused Venture Fund

Sofinnova Raises $650M Biotech-focused Venture Fund

Sofinnova News

Apr 11, 2016

12 VCs Who Matter, But You Never Read About

12 VCs Who Matter, But You Never Read About

Sofinnova News

Jan 12, 2016

Despite 'choppy' markets, fundamentals strong as health care world heads to JPM

Despite 'choppy' markets, fundamentals strong as health care world heads to JPM